T
Tego Science Inc
KOSDAQ:191420
Tego Science Inc
KOSDAQ:191420
Price:
12 890
KRW
0.39%
Market Closed
Market Cap:
₩104.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tego Science Inc
Income from Continuing Operations
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Tego Science Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Tego Science Inc
KOSDAQ:191420
|
Income from Continuing Operations
-₩3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Income from Continuing Operations
₩1T
|
CAGR 3-Years
25%
|
CAGR 5-Years
14%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Income from Continuing Operations
-₩15.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Income from Continuing Operations
-₩32.6B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Income from Continuing Operations
₩145.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
61%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Income from Continuing Operations
-₩37.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Tego Science Inc
Glance View
Tego Science, Inc. engages in the manufacture and sale of cell therapy products. The company is headquartered in Seoul, Seoul. The company went IPO on 2014-11-06. is a Korea-based company mainly engaged in the research and development, manufacture and distribution of wound-healing skin cell therapy products. The Company’s products mainly consist of cell therapy products, and laboratory cultured skin models.
Intrinsic Value
14 750.45
KRW
Undervaluation 13%
T
See Also
What is Tego Science Inc's Income from Continuing Operations?
Income from Continuing Operations
-3.3B
KRW
-3.3B
KRW
Based on the financial report for Sep 30, 2025, Tego Science Inc's Income from Continuing Operations amounts to -3.3B KRW.
